Dear colleagues and congress attendees
It is both an honor and a pleasure to welcome you to the International Ophthalmic Conference 2027.
The past two decades have seen remarkable progress in ophthalmic drug development, and vision research continues to be transformed by new knowledge and technologies. Molecular approaches such as gene therapy and mRNA-based treatments are advancing at an unprecedented pace, bringing innovative and effective therapies closer to the patients who need them. In parallel, artificial intelligence is reshaping our field at every level — from accelerating drug discovery and target identification, to enhancing diagnostic precision through automated image analysis, to enabling more personalized treatment strategies. Combined with increasingly sophisticated imaging modalities, these advances are expanding what we can observe, measure, and ultimately treat — opening new avenues for the prevention and management of blinding eye diseases.
IOC 2027 will bring together vision scientists, clinicians, researchers, healthcare professionals, patient advocacy groups, and patients themselves — all those engaged in shaping the future of ophthalmic therapies. Together, we will share the latest advances in the field and foster the kind of open, forward-looking discussions that drive our discipline forward.
I warmly invite you to join us and contribute to this exchange.
